RxDoctor Payments Data

Manu Mysore, MD

Hospitalist · Baltimore, MDNPI 1427410109

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,411 of the $3,956 with a category attached, or 61.0%. 9 manufacturers reported payments, led by Edwards Lifesciences at 47.1% of the total. Among hospitalist clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,956in general payments, 2019–2025

Across 32 payments — averaging $123.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Abbott$2K
  • Abiomed$147
  • Amgen$125
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$55
  • W. L. Gore & Associates, Inc.$50
  • plus $76 from 3 others

What the payments were for

  • Travel & lodging$2,41161%
  • Food & beverage$1,48938%
  • Education$551%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,956 in reported general payments places this provider in the 95th percentile of 414 hospitalist providers in Maryland.

See all hospitalist providers in Maryland

Medicare billing

Part B allowed, 2024
$215,163
Medicare patients
1,169
Services billed
3,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$119,138
JardianceEmpagliflozin49$66,951
EntrestoSacubitril/Valsartan62$55,064
XareltoRivaroxaban26$39,590
Praluent PenAlirocumab12$5,424
Atorvastatin Calcium135$2,126
Rosuvastatin Calcium98$1,880
Metoprolol Succinate120$1,682
Ezetimibe34$1,169
Olmesartan Medoxomil36$1,109
Nifedipine ErNifedipine21$934
ClopidogrelClopidogrel Bisulfate39$506
Amlodipine Besylate64$480
Losartan Potassium50$404
Lisinopril73$374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$119,138113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 414 hospitalist providers in Maryland.

Other hospitalist in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →